Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00444 | Maleimide-NH-PEG4-CH2CH2COOPFP Ester | 1347750-84-8 |
| Maleimide-NH-PEG4-CH2CH2COOPFP Ester is a versatile compound used in the biomedical industry for the preparation of bioconjugates. It serves as a reactive linker, enabling the conjugation of drugs or biomolecules to specific targets. Particularly, it is commonly utilized in targeted drug delivery systems for the treatment of various diseases, such as cancer and autoimmune disorders. | Inquiry | |
| BADC-00445 | Maleimide-NH-PEG3-CH2CH2COOPFP Ester | 2101206-13-5 |
| Maleimide-NH-PEG3-CH2CH2COOPFP Ester is a basic compound widely used in the biomedical field. It is an indispensable linker for coordinating the conjugation of different biomolecules, thereby accelerating the precise administration of therapeutics and diagnostics. Its widespread use in the synthesis of pioneering drug therapies and bioconjugates has led to promising clinical benefits. | Inquiry | |
| BADC-00446 | 2,5-dioxopyrrolidin-1-yl 15-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-13-oxo-3,6,9-trioxa-12-azapentadecan-1-oate | |
| 2,5-dioxopyrrolidin-1-yl 15-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-13-oxo-3,6,9-trioxa-12-azapentadecan-1-oate is a biochemical product utilized for the drug development of various diseases. It plays a crucial role in targeting specific drugs to combat infections caused by pathogens such as bacteria and viruses. | Inquiry | |
| BADC-00447 | Mal-amido-PEG2-NHS | 955094-26-5 |
| Mal-amido-PEG2-NHS is a non-cleavable ADC linker containing the Maleimide group, 2-unit PEG, and NHS ester. | Inquiry | |
| BADC-00448 | Mal-PEG-NHS | 1260092-50-9 |
| Mal-PEG-NHS is a bioconjugation reagent widely used in the biomedical industry. It is a maleimide-functionalized polyethylene glycol derivative with an NHS ester group at the other end. This compound is commonly utilized for the selective modification of proteins, peptides, and other biomolecules. It enables the conjugation of amine-containing drugs or targeting ligands to various disease-specific proteins or surfaces, thus facilitating targeted drug delivery and diagnostics. | Inquiry | |
| BADC-00449 | Mal-PEG4-PFP | 1415800-42-8 |
| Mal-PEG4-PFP ester is a PEG linker containing maleimide and PFP moieties. Maleimide is thiol-reactive and reacts between pH 6.5 and 7.5 to form thiol ester bonds. PFP moiety is amine-reactive and is less susceptible to undergoing hydrolysis. The hydrophilic PEG linker increases the water solubility of a compound in aqueous media. | Inquiry | |
| BADC-00450 | Mal-PEG4-NHS | 1325208-25-0 |
| Mal-PEG4-NHS is a non-cleavable ADC linker containing the Maleimide group, 4-unit PEG, and NHS ester. | Inquiry | |
| BADC-00451 | 2,5-dioxopyrrolidin-1-yl 2-(2-(2-(2-(2,5-dioxo-2H-pyrrol-1(5H)-yl)ethoxy)ethoxy)ethoxy)acetate | |
| 2,5-dioxopyrrolidin-1-yl 2-(2-(2-(2-(2,5-dioxo-2H-pyrrol-1(5H)-yl)ethoxy)ethoxy)ethoxy)acetate is a biomedical compound. Characterized by its complex molecular composition, it can be used as a candidate active ingredient for therapeutic intervention in a variety of diseases. Furthermore, it has potential use in the field of cancer treatment, as it disrupts the metabolic processes of malignant cells. | Inquiry | |
| BADC-00452 | Mal-PEG2-PFP | 1807512-47-5 |
| Mal-PEG2-PFP is a PEG linker containing maleimide and PFP moieties. Maleimide is thiol-reactive and reacts between pH 6.5 and 7.5 to form thiol ester bonds. PFP moiety is amine-reactive and is less susceptible to undergoing hydrolysis. The hydrophilic PEG linker increases the water solubility of a compound in aqueous media. | Inquiry | |
| BADC-00453 | Mal-PEG2-NHS ester | 1433997-01-3 |
| Mal-PEG2-NHS ester is a non-cleavable ADC linker containing the Maleimide group, 2-unit PEG, and NHS ester. | Inquiry | |
| BADC-00454 | N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-L-alanine | 1342211-31-7 |
| MC-Val-Ala-OH is a promising dipeptidyl peptidase 4 (DPP-4) inhibitor. It demonstrates the potential to reduce the breakdown of incretin hormones by inhibiting DPP-4. This intervention promotes increases in glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels, representing a pathway to superior glycemic management. | Inquiry | |
| BADC-00455 | 1-((1r,4r)-4-((2,5-dioxo-2H-pyrrol-1(5H)-yl)methyl)cyclohexanecarbonyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid | 1286837-77-1 |
| 1-((1R,4R)-4-((2,5-dioxo-2H-pyrrol-1(5H)-yl)methyl)cyclohexanecarbonyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid is an immensely potent pharmaceutical agent. Conspicuously, it demonstrates efficacy in combating diverse afflictions such as cancer and autoimmune disorders. Capitalizing on its distinct molecular configuration, it exhibits targeted activity on specific biological pathways, thereby ushering in novel prospects for efficacious therapeutic interventions. | Inquiry | |
| BADC-00456 | 2-methyl-2-(pyridin-2-yldisulfanyl)propyl 4-nitrophenyl carbonate | 1956318-90-3 |
| Inquiry | ||
| BADC-00457 | 4-nitrophenyl 2-(pyridin-2-yldisulfanyl)propyl carbonate | 1887040-81-4 |
| Inquiry | ||
| BADC-00458 | 4-nitrophenyl 2-(pyridin-2-yldisulfanyl)ethyl carbonate | 874302-76-8 |
| Inquiry | ||
| BADC-00459 | SPDP-PEG8-NHS | 1252257-56-9 |
| Inquiry | ||
| BADC-00460 | Pyridin-2-yldisulfanyl-PEG4-NHS | 1305053-43-3 |
| Inquiry | ||
| BADC-00461 | 4-succinimidyl-oxycarbonyl-α-(2-pyridyldithio)toluene | 160854-54-6 |
| Inquiry | ||
| BADC-00462 | SMPT | 112241-19-7 |
| Inquiry | ||
| BADC-00463 | N-succinimidyl-6-(2-pyridyldithio)capronate | 1824718-79-7 |
| Inquiry |
